Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. 1992

M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
Department of Medicine, Hospital del Mar, Universidad Autónoma de Barcelona, Spain.

BACKGROUND The role of lipoprotein disturbances in the development of peripheral vascular disease (PVD) has not been sufficiently clarified. RESULTS The relations among concentrations of intermediate density lipoproteins (IDL), apoprotein (apo) B, apo E, and other lipoproteins were studied in 102 men with PVD and 100 healthy men who formed the control group. Patients with PVD had significantly higher levels of serum triglycerides, very low density lipoprotein (VLDL) cholesterol, VLDL triglycerides, VLDL proteins, IDL cholesterol, and IDL triglycerides and lower levels of high density lipoproteins (HDL) than controls. Serum cholesterol and triglycerides were normal in 30 patients (cholesterol, less than 5.2 mmol/l; triglycerides, less than 2.3 mmol/l), who had significant increases in IDL triglycerides and significant decreases in HDL cholesterol compared with the 47 controls, who had normal cholesterol and triglyceride levels. Patients with more severe distal involvement showed higher cholesterol and triglycerides carried by IDL and a greater reduction in HDL cholesterol. Smoking patients with PVD showed increased VLDL cholesterol and VLDL triglycerides and lower HDL concentrations. Apo E polymorphism in our study population does not differ from that reported for other European populations. Alleles epsilon 2 and epsilon 4 had a major impact on serum triglycerides and VLDL lipids in our patients with PVD. CONCLUSIONS Lipoprotein disturbances are a major risk factor for PVD. IDL abnormalities play an important role in the development and severity of PVD and should also be considered a vascular risk factor in normocholesterolemic and normotriglyceridemic patients.

UI MeSH Term Description Entries
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
January 1982, Arteriosclerosis (Dallas, Tex.),
M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
December 1980, The Journal of biological chemistry,
M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
January 1979, Lancet (London, England),
M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
December 1989, Schweizerische medizinische Wochenschrift,
M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
January 1979, Lancet (London, England),
M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
December 1978, Lancet (London, England),
M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
August 1988, Journal of developmental physiology,
M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
July 1987, Lancet (London, England),
M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
May 1983, The Journal of biological chemistry,
M Sentí, and X Nogués, and J Pedro-Botet, and J Rubiés-Prat, and F Vidal-Barraquer
August 1989, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!